4-(acetylamino)benzeneacetic acid has been researched along with Lupus Erythematosus, Systemic in 1 studies
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, C | 1 |
| Koyama, A | 1 |
| Nishimura, T | 1 |
1 other study available for 4-(acetylamino)benzeneacetic acid and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Interleukin-2 induction, response and therapy on murine lupus lesions in the MRL/l strain.
Topics: Animals; Disease Models, Animal; Immunotherapy; Interleukin-2; Levamisole; Lupus Erythematosus, Syst | 1987 |